GlaxoSmithKline agrees to acquire Sierra Oncology for $55 a share
MLex Summary: UK-based GlaxoSmithKline has agreed to acquire San Mateo, California-based Sierra Oncology, a late-stage biopharmaceutical company, for $55 per share for an approximate equity value of $1.9 billion. The transaction...To view the full article, register now.
Already a subscriber? Click here to view full article